



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

AK

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/602,268	06/23/2003	Deryck J. Williams	12557-011001	9137
26161	7590	11/30/2005	EXAMINER	
FISH & RICHARDSON PC P.O. BOX 1022 MINNEAPOLIS, MN 55440-1022				HUTSON, RICHARD G
ART UNIT		PAPER NUMBER		
		1652		

DATE MAILED: 11/30/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/602,268	WILLIAMS ET AL.
Examiner	Art Unit	
Richard G. Hutson	1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on _____.
2a) This action is **FINAL**. 2b) This action is non-final.
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-84 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) 1-84 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date
4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. ____ .
5) Notice of Informal Patent Application (PTO-152)
6) Other:

DETAILED ACTION

Claims 1-84 are present for examination.

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

1. Claims 1-4, drawn to polypeptide related to SEQ ID NO: 7, classified in class 435, subclass 193.
2. Claims 5-8, drawn to polypeptide related to SEQ ID NO: 8, classified in class 435, subclass 193.
3. Claims 9-12, drawn to polypeptide related to SEQ ID NO: 9, classified in class 435, subclass 193.
4. Claims 13-16, drawn to polypeptide related to SEQ ID NO: 10, classified in class 435, subclass 193.
5. Claims 17-20, drawn to polypeptide related to SEQ ID NO: 11, classified in class 435, subclass 193.
6. Claims 21-24, drawn to polypeptide related to SEQ ID NO: 12, classified in class 435, subclass 193.
7. Claims 25, 31, 37, 79, drawn to a nucleic acid, classified in class 435, subclass 193.
8. Claims 26, 32, 38, 80, drawn to a nucleic acid, classified in class 435, subclass 193.

9. Claims 27, 33, 39, 81, drawn to a nucleic acid, classified in class 435, subclass 193.
10. Claims 28, 34, 40, 82, drawn to a nucleic acid, classified in class 435, subclass 193.
11. Claims 29, 35, 41, 83, drawn to a nucleic acid, classified in class 435, subclass 193.
12. Claims 30, 36, 42, 84, drawn to a nucleic acid, classified in class 435, subclass 193.
13. Claims 43, 49, 55, 61, 67, drawn to a method using the polypeptide comprising the amino acid sequence of SEQ ID NO: 7, classified in class 435, subclass 193.
14. Claims 44, 50, 56, 62, 68, drawn to a method using the polypeptide comprising the amino acid sequence of SEQ ID NO: 8, classified in class 435, subclass 193.
15. Claims 45, 51, 57, 63, 69, drawn to a method using the polypeptide comprising the amino acid sequence of SEQ ID NO: 9, classified in class 435, subclass 193.
16. Claims 46, 52, 58, 64, 70, drawn to a method using the polypeptide comprising the amino acid sequence of SEQ ID NO: 10, classified in class 435, subclass 193.

17. Claims 47, 53, 59, 65, 71, drawn to a method using the polypeptide comprising the amino acid sequence of SEQ ID NO: 11, classified in class 435, subclass 193.
18. Claims 48, 54, 60, 66, 72, drawn to a method using the polypeptide comprising the amino acid sequence of SEQ ID NO: 12, classified in class 435, subclass 193.
19. Claims 73 drawn to an antibody that binds to SEQ ID NO: 7, classified in class 435, subclass 193.
20. Claims 74, drawn to an antibody that binds to SEQ ID NO: 8, classified in class 435, subclass 193.
21. Claims 75, drawn to an antibody that binds to SEQ ID NO: 9, classified in class 435, subclass 193.
22. Claims 76, drawn to an antibody that binds to SEQ ID NO: 10, classified in class 435, subclass 193.
23. Claims 77, drawn to an antibody that binds to SEQ ID NO: 11, classified in class 435, subclass 193.
24. Claims 78, drawn to an antibody that binds to SEQ ID NO: 12, classified in class 435, subclass 193.

The inventions are distinct, each from the other because of the following reasons:
Inventions 1-2, 7-12 and 19-24 are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different

modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions, represent structurally different nucleic acid polypeptide and antibody molecules. Therefore, where structural identity is required, such as for hybridization, expression or binding the different sequences have different effects. Further, the nucleic acids can be used in hybridization assays as well as in expression methods for producing the polypeptides. The polypeptides function as transferase enzymes and the antibodies can be used to identify related polypeptides.

Inventions 1-6, respectively, and 13-18, respectively, are related as products and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the transferases of Groups 1-6 can be used in a materially different process such as one in which the polypeptides are used to synthesize antibodies.

The polynucleotide of groups 7-12 and the antibodies of groups 19-24 are unrelated to the methods of groups 13-18 as they are neither used nor made by the methods of groups 13-18.

Inventions 13-18 are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In

the instant case the different methods utilize different polypeptides and produce different results.

Because these inventions are distinct for the reasons given above, have acquired a separate status in the art as shown by their different classification, and the literature and sequence searches required for each of the Groups are not required for another of the Groups, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(l).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard G. Hutson whose telephone number is 571-272-0930. The examiner can normally be reached on M-F, 7:00-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax

phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Richard G. Hutson, Ph.D.
Primary Examiner
Art Unit 1652

rgh
11/25/2005